Evidence map›Paper›PMID 40697649›Full record

ArticleBiomaterials research2025

Keratin-Mediated Selective Inhibition in Proliferation and Selective Apoptosis of Keloid Fibroblasts.

Hyeon Jeong Kang, Woo Gyeong Kim, Seong Yeong An, Jae-Hyung Lee, Dong Nyoung Heo, Yu-Shik Hwang

Abstract read
In one paragraph

Article in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hyeon Jeong KangDepartment of Maxillofacial Biomedical Engineering, College of Dentistry, Kyung Hee University, Seoul 02447, Republic of Korea.
Woo Gyeong KimKeraMedix Inc., Seoul 02455, Republic of Korea.
Seong Yeong AnKeraMedix Inc., Seoul 02455, Republic of Korea.
Jae-Hyung LeeDepartment of Oral Microbiology, College of Dentistry, Kyung Hee University, Seoul 02447, Republic of Korea.
Dong Nyoung HeoBiofriends Inc., Seoul 02447, Republic of Korea.ORCID https://orcid.org/0000-0002-7717-7184
Yu-Shik HwangDepartment of Maxillofacial Biomedical Engineering, College of Dentistry, Kyung Hee University, Seoul 02447, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Keloids are pathological scars characterized by excessive proliferation of fibroblasts and abnormal extracellular matrix (ECM) accumulation, largely mediated by transforming growth factor-β1 (TGF-β1). Current therapeutic approaches often fail due to high recurrence and limited selectivity. Here, we investigate the potential of human hair-derived keratin (HK) as a biomaterial with selective anti-fibrotic activity. Using multiple in vitro models including 2D monolayers, 3D spheroids, fibroblast-keratinocyte coculture, and collagen gel contraction, we evaluated the effects of 0.5% HK on keloid fibroblasts (KFs) and normal dermal fibroblasts (DFs), with and without TGF-β1 stimulation. HK selectively inhibited KF proliferation, viability, and migration while sparing DF. In 3D models, HK significantly reduced KF-mediated spheroid expansion and collagen matrix contraction, even under profibrotic stimulation. Mechanistically, HK activated intrinsic apoptotic signaling, up-regulating pro-apoptotic proteins (Bax, caspase-3, CYCS) and down-regulating Bcl-2 and XIAP. Transcriptomic profiling revealed that HK down-regulated pathways associated with ECM-receptor interaction, focal adhesion, and aminoacyl-tRNA biosynthesis in KF, suggesting a dual modulation of fibrotic remodeling and mitochondrial function. These findings demonstrate that HK exerts selective anti-fibrotic and pro-apoptotic effects on pathological fibroblasts, with minimal impact on normal cells. By modulating both ECM organization and cell survival pathways, keratin demonstrates strong potential as a therapeutic biomaterial for targeted keloid treatment.

Identifiers

PMID40697649
PMCPMC12282147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.